Syndax Pharmaceuticals INC 8-K filings

Syndax Pharmaceuticals announced updates on its late-stage programs and introduced new pipeline assets, including novel inhibitors for NSCLC and myelofibrosis, during its R&D event.

Syndax Pharmaceuticals has successfully issued $250 million in 2.25% convertible senior notes due 2031 to support general corporate and R&D activities.

Syndax Pharmaceuticals stockholders approved the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at the 2026 Annual Meeting.

Syndax Pharmaceuticals has priced a $250 million offering of 2.25% Convertible Senior Notes due 2031 to fund general corporate purposes.

Syndax Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, driven by significant growth in Revuforj and Niktimvo sales, and provided positive updates on its clinical pipeline.

Syndax Pharmaceuticals announced preliminary strong 2025 revenue for Revuforj and Niktimvo, ending the year with $394 million in cash and projecting profitability.

Syndax Pharmaceuticals Inc. has amended its bylaws to transition to issuing capital stock solely in uncertificated form, effective December 18, 2025.

Syndax Pharmaceuticals announced strong third-quarter 2025 financial results, driven by significant revenue growth from its cancer therapies Revuforj and Niktimvo, alongside a key FDA approval for Revuforj.

Syndax Pharmaceuticals announced FDA approval of Revuforj (revumenib) for relapsed or refractory acute myeloid leukemia with an NPM1 mutation in adult and pediatric patients.

Syndax Pharmaceuticals reports robust Q2 2025 financial results driven by strong sales of Revuforj and Niktimvo, affirming its path to profitability.

William Meury has resigned from the Board of Directors of Syndax Pharmaceuticals, Inc., effective June 24, 2025, to assume the role of President and Chief Executive Officer at Incyte Corporation, a key collaboration partner.

Syndax Pharmaceuticals announces the appointment of Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer, succeeding Dr. Neil Gallagher.

Syndax Pharmaceuticals announces positive Q1 2025 financial results, highlighted by $34 million in combined net sales from Revuforj and Niktimvo, along with advancements in its clinical pipeline.

Syndax Pharmaceuticals announces its Q4 and full year 2024 financial results, highlighting the successful launch of Revuforj and providing a business update.

Syndax Pharmaceuticals announced the elimination of the Chief Medical Officer position, resulting in the departure of Dr. Catherine Madigan, effective December 20, 2024.

The FDA has approved Syndax Pharmaceuticals' Revuforj as the first and only menin inhibitor for treating relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients.

Syndax Pharmaceuticals reports positive topline results from the AUGMENT-101 trial for revumenib in relapsed or refractory mutant NPM1 acute myeloid leukemia, meeting its primary endpoint.

Syndax Pharmaceuticals announced its third quarter 2024 financial results, highlighted by a $350 million royalty funding agreement and progress in its clinical pipeline.

Syndax Pharmaceuticals has sold a portion of future revenue from its drug axatilimab to Royalty Pharma for $350 million.

Syndax Pharmaceuticals announced its second quarter 2024 financial results and provided updates on its clinical pipeline, including upcoming PDUFA dates for axatilimab and revumenib.

Syndax Pharmaceuticals has appointed Dr. Aleksandra Rizo to its Board of Directors, effective immediately, replacing Dr. Briggs Morrison who has stepped down.

Syndax Pharmaceuticals announced its first quarter 2024 financial results, highlighted by priority review designations for two key drug candidates and progress in clinical trials.

Syndax Pharmaceuticals has appointed Steven Closter as its new Chief Commercial Officer, effective immediately, to lead the company's commercial strategy and operations.

Syndax Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting significant clinical and regulatory advancements, including BLA filing for axatilimab and NDA submission for revumenib.